SPX4,297.14+16.99 0.40%
DIA339.37+1.54 0.46%
IXIC13,128.05+80.87 0.62%

BRIEF-Cyclerion Reports Positive Topline Clinical Data For CY6463

BRIEF-Cyclerion Reports Positive Topline Clinical Data For CY6463

Reuters · 07/28/2022 07:31
BRIEF-Cyclerion Reports Positive Topline Clinical Data For CY6463

- Cyclerion Therapeutics Inc CYCN:

  • CYCLERION THERAPEUTICS ANNOUNCES POSITIVE TOPLINE CLINICAL DATA FOR CY6463 IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS)

  • CYCLERION - DATA SHOW POSITIVE EFFECTS OF CY6463 ON COGNITION & INFLAMMATION AFTER 2 WEEKS OF DOSING IN PATIENTS WITH STABLE SCHIZOPHRENIA ON STANDARD OF CARE

  • CYCLERION THERAPEUTICS - ORAL, ONCE-DAILY CY6463 WELL TOLERATED, NO REPORTS OF SERIOUS ADVERSE EVENTS OR TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS

Source text for Eikon: ID:

Further company coverage: CYCN


((Reuters.Briefs@thomsonreuters.com;))